Going from 1.7mg to 2.4mg Wegovy: making the decision to move up

Why 2.4mg is the destination, not just the next number

Every previous dose increase on Wegovy (from 0.25mg through 0.5mg, 1mg and 1.7mg) exists to condition your digestive system, not to produce the main therapeutic effect. The titration schedule is essentially a tolerance-building runway. At 2.4mg, the medicine reaches its licensed maintenance level, and this is where the bulk of the clinical evidence sits. The STEP 1 trial, published in the New England Journal of Medicine, ran 68 weeks at 2.4mg and found average weight loss of around 15% in adults with obesity. That figure is not guaranteed for any individual, but it represents the dose at which semaglutide's appetite-suppressing effects are fully established.

Understanding this matters when you are sitting at 1.7mg feeling ambivalent. If your weight loss has slowed and side effects have settled, 2.4mg may deliver a meaningful additional benefit. If nausea is still interrupting daily life at 1.7mg, moving up before you are ready risks making things worse rather than better. The step is not automatic. A prescriber reviewing your progress will look at how your body responded at 1.7mg, how your weight has moved, and whether any new symptoms have emerged. If you want a closer look at what the transition from 1mg to 1.7mg involved, that earlier step provides useful context for how your body has already adapted. For a fuller picture of how the full dose schedule is structured, the Wegovy dose guide covers each stage in detail.

What the move to 2.4mg tends to feel like

The most predictable thing about any dose increase on Wegovy is that nausea, if it is going to return, tends to peak in the first one to two weeks. This is not a sign that something has gone wrong. It is the same transient GI response that appeared, for most people, at every previous step. Common symptoms include nausea, loose stools, constipation, stomach discomfort, and feeling full very quickly after small meals. Most people find these settle within a fortnight, sometimes sooner.

A few practical things help. Keeping meals small and protein-rich, avoiding fatty or very rich food while the body adjusts, and staying well hydrated all reduce the severity of GI symptoms without requiring any change to the prescription. Some people find it useful to take their weekly injection on a day when a lighter schedule means they can rest if needed, a Friday injection for a quieter weekend, for instance. The pen itself stays in the fridge alongside the others; the injection-day routine does not change at 2.4mg. What does change is appetite, which for many people falls noticeably further in the weeks after the dose increase.

If symptoms at 2.4mg are severe or persistent beyond two weeks, the right move is to contact your prescriber, not to skip doses or self-adjust. The 2.4mg dose page covers the specific profile of this maintenance dose in more detail, and the NHS medicines page for semaglutide sets out the full side-effect picture alongside advice on when to seek urgent help.

When staying at 1.7mg is the right call

Not everyone moves to 2.4mg. That is not a failure. NICE's guidance on semaglutide (TA875) frames the goal as maximum tolerated dose, not maximum dose, so if 1.7mg is being tolerated well and producing meaningful weight loss, a prescriber may choose to remain there for a period before reassessing. If 1.7mg is still causing persistent side effects, jumping to 2.4mg before those have resolved makes the whole treatment harder to sustain. Long-term adherence matters more than hitting the top number quickly. You can read about the broader landscape of dose increases on Wegovy including what the clinical thinking looks like at each transition.

Some people also find that weight loss stalls at 1.7mg and wonders whether that alone is reason to increase. A plateau is worth discussing with your prescriber, but it is not on its own a guarantee that 2.4mg will break it, other factors, including diet, activity, sleep and stress, all interact with how the medicine performs. The prescriber's job is to weigh all of this, not to simply tick the dose box.

How clinical oversight at this step works

At nume, every dose change requires a clinical re-review. A prescriber reads your update (not a bot, not an automated flag) and considers your reported progress and any symptoms before a new prescription is issued. There is no auto-renewal that bumps you up without that review. If you are transferring from another provider and already established at 1.7mg and seeking to move to 2.4mg, evidence of your current dose and recent progress will be needed; our Wegovy treatment page explains what that process looks like.

This kind of oversight is what distinguishes a regulated online pharmacy from informal channels. For anyone researching how to access Wegovy safely, the where to buy Wegovy page covers what to look for in a provider and how to verify any pharmacy on the GPhC register. Cost is a natural part of that research too; if you want context on what private treatment involves financially, our treatment and pricing page sets it out plainly, without subscription charges or hidden fees. Once you are ready to discuss your next step, you can check your eligibility and start a free consultation.